Winter 2024 Investor Summit Virtual 40 MicroCap Presenters – November 21, 2024 9:00am-4:00pm ET – Company Presentations 8:00am-4:00pm – 1×1 Meetings Register Q4 Presenters TNXP Tonix submitted a New Drug Application to the FDA in October 2024. An FDA decision on the NDA is expected in 2025, with potential product launch in 2025 if approved. URG Largest U.S. uranium miner Nuclear energy sector is in rapid growth TMGEF Proprietary energy efficiency solutions provide high ROI Track record of profitable growth with significant repeat business from F500 TGCB Product, people, plan, opportunity = success Commercial success is in process MFIN MFIN has a proven track record of growing loan portfolio. Above average NIM gives flexibility and options. MAIA Unprecedented efficacy clinical data in current clinical trial with a supply agreement with Regeneron. Ongoing discussions with potential major pharma partners for next trials One of the most undervalued biotech stocks in Oncology: analysts project $10-14/share in 2025; analogs suggest $50- AZ Timing of self-checkout, specifically Smart cart adoption, is starting to broadly happen among more and more grocery chains. Strong momentum with notable international and domestic grocery store and wholesale chains. Rollout and implementation of our smart carts to commence in earnest in Q1. Publicly announced two IT partnerships that represent two NMTC Thin-film electrode platform technology with multiple market opportunities treating and diagnosing neurological disorders and pain. Improving financial profile. Now have 3 product families commercialized in the United States. NRBO Targeting Obesity and MASH with a Pipeline of Next Generation Therapeutics Aiming to increase Shareholder Value through Multiple, Near-Term, Value Creating Milestones DA-1726 IMUX Immunic is developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases Top-line data from the phase 2 CALLIPER trial of vidofludimus calcium in PMS is expected in April 2025 BLGO Has a proven business model of inventing, proving, and partnering out its innovative environmental technologies, highlighted by the blockbuster success of its pet odor control product Pooph. Has innovations in high-yield, rapidly growing markets like battery energy storage and PFAS treatment that are superior to existing solutions in the market. SOTK Consistently profitable with strong growth trajectory in disruptive high tech markets. Record revenue in Fiscal year 2024, 30% YOY growth. ACFN Liquidity of the shares will improve with performance and as the price increases towards intrinsic value. Acorn's results are just starting to reflect a large contract with a leading Telecom provider. OESX FY’25 revenue expected to increase 10% weighted toward the 2H. EV charging grew 40% in Q2; $7.5B of Federal funding appropriated for EV infrastructure. FET Increasing global energy demand will propel long-term investment Global footprint and strategy execution will drive strong free cash flow BENF Innovative access to private equity investments via public equity stock Transitioned to GAAP net income profitable operations in F1Q 2025 (June 30 Quarter End) IMRN September 2024 Quarter AUD$1.5 million up 13% on prior quarter Sales of Travelan® increased 3% to AUD $1.007 million during September 2024 Quarter LMFA Held 142.3 Bitcoin on September 30, 2024, Valued at Approximately $12.4 Million Based on Recent Bitcoin Price of $87,000 Digital mining cost of revenues (exclusive of depreciation and amortization) as a percentage of digital mining revenues showed substantial improvement versus the prior year quarter. ACON Industry 1st noninvasive diagnostic with strong clinical evidence of value Nearly 60% of all patients with private health insurance in the greater London market now have Access to Aclarion’s Nociscan AUUD Leading the audio superapp space with differentiation & margin Accretive M&A strategy to accelerate revenue & user acquisitions SNGX Robust pipeline with multiple fast track and/or orphan designated products, potential for significant commercial returns Late clinical-stage assets, one with successful Phase 3 data readout CPSH Unique applications in rapidly-expanding markets Strong balance sheet New contract wins At inflection point for growth ASNS Actelis is growing as the results of the year to-date can attest to, showing nearly 50% growth year over year, gross margin grew and net loss/EBITDA shrunk dramatically. The company is expanding its reach into several segments such as cyber security of IoT devices in roads, cities, and more as well as multi-dwelling units PERF Industry growth potential in beauty/fashion tech PERF's strength and innovations for growth in B2B (SAAS) and B2C (suite of apps under YouCam brand). ULY Leading proprietary digitally native mobility services platform Uniquely positioned to further penetrate $25B B2B incident business opportunity PLUR $10m raise in EverAfter Foods from Global Food Giants as Strategic Partners Innovative collaborations with multi-national agriculture corporations - €1 million POC project SPGC 3Q24 revenue +1163% YOY and +48% QoQ Newton Motion replacement shafts is company's key product line and is showing significant growth and even gaining traction with professional golfers. HLRTF Investor Presenter Q3 Presenters CVKD CXDO COCP FAAS FEMY PRSO PRPH SWAG TGCB REAX TNXP URG VBNK VFF CAN VFS BENF CDZI DCGO PLUR SPGC GNS MFIN HLRTF ASNS SNGX LIXT AENT NVCT ACON SHPH KDLY OPFI TMGEF RUM TBRD SOTK VCIG AUUD UNCY
